(September 1, 2016, 3:54 PM EDT) -- WASHINGTON, D.C. — An appellate court’s interpretation of the Hatch-Waxman safe harbor, 35 U.S. Code Section 271(e)(1), is “overly narrow” and puts generic manufacturers at risk of patent suits, Amphastar Pharmaceuticals Inc., International Medication Systems Ltd., Actavis Inc. and Actavis Pharma Inc. (Amphastar, collectively) argue in an Aug. 16 reply brief to the U.S. Supreme Court (Amphastar Pharmaceuticals, Inc., et al. v. Momenta Pharmaceuticals, Inc. and Sandoz, Inc., No. 15-1402, U.S. Sup.)....